The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.
All entries for: Chronic Disease
April 29, 2025
AnaptysBio
Negative Outlook
San Diego, CA
51-200 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Biologic
April 29, 2025
Verona Pharma
Neutral Outlook
Raleigh, NC
201-500 employees
The impact of the IRA on our company and the pharmaceutical industry cannot yet be fully determined but is likely to be significant.
Disease Area: Chronic Disease, Multiple, Respiratory Diseases
Drug Type: Small Molecule
April 2, 2025
Gilead Sciences
Layoffs
Foster City, CA
10,000+ employees
Gilead is trimming its California workforce by 149, according to a WARN Notice posted last week. The layoffs will take effect on May 27 and will affect scientific and technical services at the pharma’s site in Foster City.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 13, 2025
Kojin Therapeutics
Discontinued Research
Boston, MA
1-50 employees
“Kojin Therapeutics will be restructuring and winding down its operations in the coming months. Since last year, with a new leadership team in place, we have made striking progress in developing first-in-class, small-molecule, ferroptosis inducers for potential use in patients with cancer and autoimmune diseases. However, obtaining sufficient funding to propel these programs forward into IND-enabling studies and clinical trials has proven difficult to achieve.”
1 Discontinued Research Program
Disease Area: Chronic Disease, Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
February 5, 2025
Takeda - Cambridge
Discontinued Research
Cambridge, MA
10,000+ employees
The clinical trial titled “A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)” (NCT06768658), sponsored by Takeda, was terminated due to business reasons before enrolling any participants. Specific details regarding these business reasons were not disclosed.
1 Discontinued Research Program
Disease Area: Chronic Disease
Drug Type: Small Molecule
January 10, 2025
IGM Biosciences
Discontinued Drug, Discontinued Research, Layoffs
Mountain View, CA
201-500 employees
“Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.
IGM Biosciences is cutting 73% of its workforce and stopping development of two autoimmune drug candidates, the biotech announced Jan. 9…
Regarding its pipeline, IGM is halting work on imvotamab and IGM-2644, bispecific antibody T cell engagers for autoimmune diseases. In the company’s announcement, IGM CEO Mary Beth Harler said interim data from Phase Ib studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus showed that the depth and consistency of B cell depletion didn’t meet the biotech’s bar for success. She noted that IGM would discontinue IGM-2644 due to strategic considerations.
The biotech is also considering its next business move so it can maximize shareholder value, in part by evaluating “internal options as well as potential strategic alternatives,” according to the release, which stated that IGM has about $183.8 million in cash and investments as of Dec. 31.”
1 Discontinued Drug: IGM-2644, bispecific antibody T cell engager for autoimmune diseases
1 Discontinued Research Program
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Biologic
January 8, 2025
Galapagos - Cambridge
Discontinued Research, Layoffs
Cambridge, MA
1,001-5,000 employees
“To advance its goal of becoming a global leader in cell therapy in oncology, Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over its small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.”
2 Discontinued Research Programs
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Small Molecule
October 31, 2024
Alnylam
Discontinued Drug, Discontinued Research
Cambridge, MA
1,001-5,000 employees
“Today announced the decision to suspend further clinical development of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase for the treatment of type 2 diabetes mellitus. This decision reflects portfolio prioritization efforts to allocate clinical, managerial and financial resources carefully to bring transformative medicines to patients.”
1 Discontinued Drug: ALN-KHK (biologic)
1 Discontinued Research Program
Disease Area: Chronic Disease
Drug Type: Biologic